Rosuvastatin + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Aortic Stenosis

Conditions

Aortic Stenosis

Trial Timeline

Nov 1, 2002 → Sep 1, 2008

NCT ID

NCT00800800

About Rosuvastatin + Placebo

Rosuvastatin + Placebo is a phase 3 stage product being developed by AstraZeneca for Aortic Stenosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00800800. Target conditions include Aortic Stenosis.

What happened to similar drugs?

6 of 13 similar drugs in Aortic Stenosis were approved

Approved (6) Terminated (4) Active (5)

❌Apixaban 5 MG + Apixaban 2.5 MG + WarfarinArtivionPhase 3

🔄EdoxabanDaiichi SankyoPhase 3

✅NOAC + DAPTDaiichi SankyoApproved

🔄candesartan + placeboAstraZenecaPhase 3

✅SugammadexMerckApproved

✅bisoprolol + placeboMerckApproved

✅atorvastatin (Lipitor)PfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02546323	Phase 3	Completed	Sep 17, 2015	Jan 29, 2019	Atherosclerosis
NCT00929734	Phase 2	Completed	Mar 1, 2010	Jan 1, 2014	Chronic Obstructive Pulmonary Disease (COPD)
NCT00951132	Phase 2	Withdrawn	Sep 1, 2009	Dec 1, 2013	Depression
NCT00990028	Phase 1/2	Completed	Aug 1, 2009	Aug 1, 2011	Head Injury
NCT00783042	Phase 1	Completed	Oct 1, 2008	May 1, 2009	Atherosclerosis
NCT00673582	Approved	Terminated	Apr 1, 2008	Mar 1, 2013	Atherosclerosis
NCT00689416	Phase 1	Completed	Dec 1, 2007	Jun 1, 2009	Atherosclerosis
NCT00329758	Phase 2	Completed	Jul 1, 2006	Oct 1, 2007	Head Injury
NCT00355615	Phase 3	Completed	Jul 1, 2006	Jul 1, 2008	Familial Hypercholesterolemia
NCT00658463	Approved	Completed	Jan 1, 2006	Sep 1, 2007	Diabetes
NCT00800800	Phase 3	Completed	Nov 1, 2002	Sep 1, 2008	Aortic Stenosis

Competing Products

20 competing products in Aortic Stenosis

See all competitors

Product	Company	Stage	Hype Score
Apixaban 5 MG + Apixaban 2.5 MG + Warfarin	Artivion	Phase 3	26
Edoxaban	Daiichi Sankyo	Phase 3	36
NOAC + DAPT	Daiichi Sankyo	Approved	43
Ticagrelor + Placebo	AstraZeneca	Phase 2	35
candesartan + placebo	AstraZeneca	Phase 3	36
Sugammadex	Merck	Approved	43
bisoprolol + placebo	Merck	Approved	35
Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet	Merck	Phase 2/3	42
Pelacarsen (TQJ230) 80mg + Matching placebo	Novartis	Phase 2	42
fluvastatin	Novartis	Phase 2	31
ACZ885 + Placebo	Novartis	Phase 2	27
Evolocumab + Placebo	Amgen	Phase 1	36
atorvastatin (Lipitor)	Pfizer	Approved	35
Apixaban + Standard of care	Pfizer	Phase 3	40
Ataciguat + Placebo	Sanofi	Phase 1	29
Ataciguat (HMR1766)	Sanofi	Phase 2	35
Haemocomplettan® P + Saline solution	CSL	Phase 2	35
Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA)	Bayer	Phase 3	29
Acetylsalicylic acid + Clopidogrel + Rivaroxaban	Bayer	Phase 3	37
Desflurane	Baxter	Approved	36